AstraZeneca PLC (LON:AZN) Ratings Coverage

In total 12 analysts cover AstraZeneca PLC (LON:AZN). “Buy” rating has 7, “Sell” are 0, while 5 are “Hold”. (LON:AZN) has 58% bullish analysts. 62 are the (LON:AZN)’s ratings reports on Feb 25, 2019 according to StockzIntelligence Inc. On Monday, November 19 Barclays Capital maintained the shares of AZN in report with “Overweight” rating. On Tuesday, November 6 Shore Capital maintained AstraZeneca PLC (LON:AZN) with “Hold” rating. On Tuesday, February 5 the stock of AstraZeneca PLC (LON:AZN) earned “Overweight” rating by Barclays Capital. The stock rating was maintained by JP Morgan with “Overweight” on Friday, October 19. On Thursday, November 1 the stock of AstraZeneca PLC (LON:AZN) earned “Outperform” rating by Credit Suisse. On Tuesday, October 16 the stock has “Hold” rating by Shore Capital. On Tuesday, October 30 the firm earned “Hold” rating by Shore Capital. On Friday, September 7 the stock has “Hold” rating by Shore Capital. The company rating was maintained by JP Morgan on Monday, November 19. On Tuesday, September 25 Deutsche Bank maintained the shares of AZN in report with “Buy” rating. Listed here are AstraZeneca PLC (LON:AZN) PTs and latest ratings.

25/02/2019 Broker: Shore Capital Rating: Buy Maintain
22/02/2019 Broker: Bryan Garnier & Cie Rating: Neutral Old Target: GBX 6220.00 Downgrade
19/02/2019 Broker: Shore Capital Rating: Buy Maintain
18/02/2019 Broker: Deutsche Bank Rating: Buy Old Target: GBX 6900.00 Maintain
14/02/2019 Broker: Shore Capital Rating: Buy Maintain
14/02/2019 Broker: Liberum Capital Rating: Hold Old Target: GBX 5800.00 Maintain
05/02/2019 Broker: Barclays Capital Rating: Overweight Old Target: GBX 6800.00 Maintain
05/02/2019 Broker: Shore Capital Rating: Buy Maintain
25/01/2019 Broker: Shore Capital Rating: Buy Downgrade
21/01/2019 Broker: Barclays Capital Rating: Overweight Old Target: GBX 6800.00 Maintain

AZN is reaching GBX 6274 during the last trading session, after increased 1.87%.Currently AstraZeneca PLC is after 0.00% change in last February 25, 2018. AZN has 955,694 shares volume. AZN the S&P500 by 0.00%.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.The company has 79.50 billion GBP market cap. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.The P/E ratio is 36.91. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Another two news for AstraZeneca PLC (LON:AZN) were briefly posted by: on December 25, 2017 with title “What Investors Should Know About AstraZeneca PLC’s (LON:AZN) Financial Strength – Yahoo Finance”. The other ‘s article was titled “How Does AstraZeneca PLC (LON:AZN) Fare As A Dividend Stock? – Yahoo Finance” and posted on June 01, 2018.